Introduction
============

Interferon (IFN) exerts antiviral, antiproliferative, and immunomodulatory actions,[@b1-cmed-4-2011-039] and is used extensively for the treatment of chronic hepatitis C (HCV). Ribavirin (RBV), an antiviral agent, has been reported to reinforce the therapeutic effect of IFN in patients with chronic HCV.[@b2-cmed-4-2011-039] In recent years, combined pegylated interferon (PEG-IFN)+RBV therapy has been used as a primary treatment for chronic HCV. However, IFN-induced autoimmune disease has been highlighted as one of the problems with this therapy. In 1992, Fabris et al reported the case of a patient with HCV who developed type 1 diabetes mellitus following treatment with IFNα.[@b3-cmed-4-2011-039] Since then, cases of type 1 diabetes mellitus associated with IFN monotherapy or combined IFN+RBV therapy have been reported sporadically. IFN therapy is usually discontinued when type 1 diabetes mellitus is diagnosed in these patients. However, a few cases in which IFN therapy was continued even after the diagnosis of type 1 diabetes mellitus have also been reported. We report here the case of a patient who developed type 1 diabetes mellitus during combined PEG-IFNα+RBV therapy for HCV, who showed no worsening of diabetes despite continued use of IFN.

Case Report
===========

A 63-year-old man presented to our hospital with excessive thirst, polydipsia, and polyuria. He had been diagnosed as having acute hepatitis B at age 35 years, at which time a liver biopsy had resulted in massive bleeding requiring blood transfusion. At age 48 years, he was diagnosed as having chronic HCV (genotype 1b). IFNα therapy for chronic HCV was administered at ages 50 years and 60 years, but the treatment failed to achieve negative conversion of serum HCV-RNA.

At age 63 years, PEG-IFNα+RBV was administered, and serum HCV-RNA became negative eight weeks after the start of this treatment. From week 16 onwards, the fasting plasma glucose level began to rise gradually from 5.0 mmol/L to 9.9 mmol/L. During week 24, the patient began to complain of excessive thirst, polydipsia, and polyuria. The patient had never been found to have abnormal glucose tolerance before. There was no family history of diabetes mellitus.

Physical findings on admission were height 165 cm, body weight 66 kg, body mass index 24.2 kg/m^2^, and blood pressure 120/72 mmHg. His consciousness level was normal. Examination of the heart, lungs, and abdomen was also normal. No abnormalities were detected on neurological examination.

Mild anemia was noted (red blood cell count and hemoglobin 379 × 10^4^/μL and 11.2 g/dL, respectively), but there were no abnormalities of the other blood cell parameters. Fasting plasma glucose was 16.2 mmol/L, serum glycosylated hemoglobin was 10.0% (Japan Diabetes Society), and serum glycoalbumin was 39.3%. There were no abnormalities in serum electrolyte profile, liver function, or renal function. Microalbuminuria was noted (urinary albumin, 56.4 mg/gcreatinine). The C-peptide level was 0.68 ng/mL (normal 1.00-- 2.00 ng/mL), fasting immunoreactive insulin was 3.0 μU/mL(normal 3.06--16.9 μU/mL), and the serum antiglutamic acid decarboxylase antibody titer was markedly elevated at 27,700 U/mL (normal \< 1.5 U/mL). Based on these findings, a diagnosis of type 1 diabetes mellitus was made. HLA DNA typing revealed DRB1\*0101/\*0405, which was not inconsistent with the diagnosis of type 1 diabetes mellitus.

Because the patient had HCV genotype 1b, which needed 48 weeks of combined PEG-IFNα+RBV therapy,[@b4-cmed-4-2011-039] the treatment was continued even after diagnosis of diabetes mellitus, until 48 weeks with careful observation of plasma glucose levels. Serum HCV remains negative five years after this treatment. Intensive insulin therapy was started immediately after the diagnosis for treatment of type 1 diabetes mellitus. The patient initially required 22 U of insulin per day (insulin glargine 10 U, insulin as part 4--4--4 U); however, the dosage could be gradually reduced after completion of PEG-IFN+RBV therapy. At present, plasma glucose is well controlled (glycosylated hemoglobin 5.7%--6.5%), with only 6 U of insulin aspart needed per day. Serum antiglutamic acid decarboxylase antibody titers also decreased gradually from the initial 27,700 U/mL to about 900 U/mL at four years after the diagnosis.

Discussion
==========

It has been reported that insulin resistance may develop as a result of interference in intracellular insulin signaling by HCV proteins, mainly viaserine phosphorylation of IRS-1 and impairment of the downstream Akt signaling pathway.[@b5-cmed-4-2011-039] According to a report by Mehta et al, the incidence of type 2 diabetes mellitus is about three times higher in HCV-infected individuals than in noninfected individuals overthe age of 40 years.[@b6-cmed-4-2011-039] In contrast it has also been reported that the incidence of type 1 diabetes mellitus as a complication is lower than that of type 2 diabetes mellitus.[@b7-cmed-4-2011-039] It has also been reported that the pancreas-associated autoantibody (including antiglutamic acid decarboxylase antibody) positivity rate in HCV patients is 3% before the start of IFN therapy but increases to 7% thereafter.[@b1-cmed-4-2011-039] Thus, IFN therapy seems to be associated with the onset of diabetes mellitus mediated by the autoimmune system. Whether or not the type 1 diabetes mellitus that developed in the present case was associated with IFN+RBV therapy is an interesting point. No evidence of development of diabetes mellitus was seen during the first two sessions of IFN therapy; however, considering that the blood glucose level began to rise four months after the administration of IFNα+RBV therapy, it is unlikely that this patient would developed diabetes mellitus before the start of this therapy, and the most reasonable interpretation would be that the IFNα+RBV therapy was causatively associated with the onset of type 1 diabetes mellitus. Because pancreas-associated autoantibodies had not been measured before the start of IFNα+RBV therapy, it is unknown whether the timing of the start of this therapy coincided with onset of type 1 diabetes mellitus or whether the patient had developed slowly progressive type 1 diabetes before the start of the IFNα+RBV.

Twenty-eight cases of type 1 diabetes mellitus diagnosed after the start of IFN+RBV therapy have thus far been reported in the English language literature.[@b3-cmed-4-2011-039],[@b8-cmed-4-2011-039]--[@b25-cmed-4-2011-039] We reviewed the data for each of these cases, focusing on the length of time from the start of IFN+RBV therapy to the onset of type 1 diabetes mellitus, continuation/ discontinuation of IFN therapy after the onset of type 1 diabetes, weaning/nonweaning from insulin therapy after discontinuation of IFN+RBV, presence/absence of pancreas-associated autoantibodies before and after IFN+RBV therapy, and the HLA haplotype of the patients ([Table 1](#t1-cmed-4-2011-039){ref-type="table"}). While in most cases IFN+RBV therapy had been discontinued immediately after the diagnosis of type 1 diabetes,[@b3-cmed-4-2011-039],[@b8-cmed-4-2011-039]--[@b16-cmed-4-2011-039],[@b18-cmed-4-2011-039],[@b20-cmed-4-2011-039]--[@b24-cmed-4-2011-039] the treatment had been continued in two cases, including the present case.[@b25-cmed-4-2011-039] Insulin therapy could be discontinued later in only two of the 19 cases in which IFN+RBV therapy had been stopped immediately after the diagnosis of type 1 diabetes.[@b8-cmed-4-2011-039],[@b23-cmed-4-2011-039] Weaning from insulin therapy appears to be difficult in cases of type 1 diabetes mellitus developing after the start of IFN+RBV therapy, and it has been reported that weaning was impossible in 75% of such cases.[@b1-cmed-4-2011-039] A report of cases of type 1 diabetes mellitus developing after completion of IFN+RBVtherapy[@b19-cmed-4-2011-039] suggests that discontinuation of IFN+RBV therapy does not always suppress the onset of type 1 diabetes mellitus. After the onset of type 1 diabetes, insulin secretion was improved three months later by strict control of diabetes in case 2, and insulin treatment could be canceled 14 months later in case 24. Therefore, if strict blood glucose control is possible regardless of continuation/ discontinuation of IFN+RBV therapy, it would seem possible to reduce the insulin dose required eventually, as achieved in the present case (probably the so-called "honeymoon phenomenon"). In this sense, strict control of diabetes is essential when dealing with such cases.

As shown in [Table 1](#t1-cmed-4-2011-039){ref-type="table"}, among the 28 reported patients, 19 had undergone measurement of pancreas-associated autoantibodies before the start of IFNRBV therapy,[@b3-cmed-4-2011-039],[@b9-cmed-4-2011-039]--[@b13-cmed-4-2011-039],[@b15-cmed-4-2011-039]--[@b17-cmed-4-2011-039],[@b19-cmed-4-2011-039]--[@b21-cmed-4-2011-039] which revealed 10 antibody-positive cases[@b3-cmed-4-2011-039],[@b9-cmed-4-2011-039],[@b11-cmed-4-2011-039],[@b13-cmed-4-2011-039],[@b14-cmed-4-2011-039],[@b16-cmed-4-2011-039],[@b19-cmed-4-2011-039] and nine antibody-negative cases.[@b10-cmed-4-2011-039]--[@b12-cmed-4-2011-039],[@b17-cmed-4-2011-039],[@b19-cmed-4-2011-039]--[@b21-cmed-4-2011-039] On the other hand, after the start of treatment, autoantibodies were positive in 27 of the 28 cases. Autoantibodies remained negative in only one case; however, a diagnosis of type 1 diabetes mellitus was made on the basis of the clinical course and capacity for insulin secretion. [@b11-cmed-4-2011-039] Although checking for pancreas-associated autoantibodies before the start of IFN+RBV therapy may seem valid, it would appear to be difficult to predict the onset of type 1 diabetes mellituson the basis of the results. Rather than checking for pancreas-associated autoantibodies, checking for the HLA haplotype before the start of this therapy may be more useful to predict the onset of type 1 diabetes mellitus, in view of reports that the HLA haplotype may be closely involved in the onset of type 1 diabetes mellitus associated with IFN+RBV therapy.[@b1-cmed-4-2011-039],[@b19-cmed-4-2011-039] However, because checking of the HLA haplotype is an expensive investigation and type 1 diabetes mellitus is a rare complication of IFN+RBV therapy, it may be difficult to perform this test in all cases. It would therefore be advisable to bear in mind the possibility of onset of type 1 diabetes mellitus when IFN+RBV therapy is administered.

IFN causes a shift in the Th1/Th2 balance to a Th1-predominant state, which results in induction of Th1-type cytokines, such as IFN-γ and interleukin 2. These cytokines activate macrophages, natural killer cells, and cytotoxic T lymphocytes, resulting in exaggerated cellular immune responses.[@b1-cmed-4-2011-039],[@b26-cmed-4-2011-039],[@b27-cmed-4-2011-039] The Th1-predominant state also seems to amplify autoimmune responses, accelerating β cell destruction in the pancreas. Alternatively, it is possible that Th1-type cytokines induce the Fas antigen on the β cell surface, resulting in cellular apoptosis, or that free radicals formed by the actions of cytokines serve as cytotoxic factors for β cells.[@b28-cmed-4-2011-039],[@b29-cmed-4-2011-039] RBV also has the effect of causing a shift in the Th1/Th2 balance to a Th1-predominant state, reinforcing IFN-induced activation of cellular immunity in a synergistic manner.[@b30-cmed-4-2011-039] In the present case, three sessions of IFN+RBV therapy were administered; however, hyperglycemia was not noted during the first two sessions. Although it is highly probable that addition of RBV to IFN therapy caused the onset of type 1 diabetes mellitus in the present case, further data is needed to examine whether or not IFN+RBV therapy might be associated with an elevated risk of developing type 1 diabetes mellitus as compared with use of IFN therapy alone.

Conclusion
==========

We encountered a patient who was diagnosed as having type 1 diabetes mellitus during combined PEG-IFNα+ RBV therapy, in whom no aggravation of diabetes was found despite continued use of IFNα+RBV therapy. Prediction of the onset of type 1 diabetes mellitus is difficult based on the baseline measurement of pancreas-associated autoantibodies alone. Therefore, it would be advisable to bear in mind the possibility of onset of type 1 diabetes mellitus in all patients treated with IFN+RBV.
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###### 

Main clinical, immunological and genetic features of 28 patients with chronic type C viral hepatitis who developed type 1 diabetes mellitus associated with interferon treatment.

  **Case**   **Age**   **Gender**   **Latency before T1DM (month)**   **Continue of IFN**   **Improvement of DM after withdrowal of IFN**   **Anti-islet antibody**   **Type of IFN**   **HLA typing**   **Ref**                              
  ---------- --------- ------------ --------------------------------- --------------------- ----------------------------------------------- ------------------------- ----------------- ---------------- ------------------------------------ ------------------------
  1          61        M            6                                 (−)                   Nimp                                            (+)                       (+)               α2b              DRB1\*0401/\*1101, DQB1\*0502/0503   [@b3-cmed-4-2011-039]
  2          59        F            4                                 (−)                   Imp                                             ND                        (+)               α                DR4                                  [@b8-cmed-4-2011-039]
  3          29        M            5                                 (−)                   Nimp                                            (+)                       (+)               α2b              DRB1\*04/\*08, DQB1 57N-Asp/Asp      [@b9-cmed-4-2011-039]
  4          57        M            4                                 (−)                   Nimp                                            (−)                       (+)               α2b              DRB1\*0405/\*1401, DQB1\*0401/0503   [@b10-cmed-4-2011-039]
  5          41        M            3                                 (−)                   Nimp                                            (−)                       (−)               α2b+REV          DRB1\*0101/\*0401                    [@b11-cmed-4-2011-039]
  6          36        F            3                                 (−)                   Nimp                                            (+)                       (+)               α2b+ REV         ND                                   [@b11-cmed-4-2011-039]
  7          29        M            8.5                               (−)                   Nimp                                            (−)                       (+)               α                DrB1\*0301, DQB1\*0201               [@b12-cmed-4-2011-039]
  8          37        M            7.5                               (−)                   Nimp                                            (+)                       (+)               α2b+ REV         DR1/3                                [@b13-cmed-4-2011-039]
  9          53        F            5                                 (−)                   Nimp                                            ND                        (+)               α2b+ REV         ND                                   [@b14-cmed-4-2011-039]
  10         40        F            6                                 (−)                   Nimp                                            (+)                       (+)               α2b+ REV         DR4/7, DQ2/8                         [@b15-cmed-4-2011-039]
  11         40        F            2                                 (−)                   Nimp                                            (+)                       (+)               α2b+ REV         ND                                   [@b15-cmed-4-2011-039]
  12         61        M            3                                 (−)                   Nimp                                            (+)                       (+)               PEG-α2b+ REV     DRB1\*04/\*14, DQB1\*04/\*0503       [@b16-cmed-4-2011-039]
  13         42        F            2                                 ND                    Nimp                                            (−)                       (+)               PEG-α2b+ REV     DR1/4, DQ2/5                         [@b17-cmed-4-2011-039]
  14         38        F            4                                 (−)                   Nimp                                            ND                        (+)               PEG-α2a+ REV     DRB1\*03, DQB1\*02                   [@b18-cmed-4-2011-039]
  15         54        M            4 after IFN                       ND                    ND                                              (±)                       (±)               PEG-α+ REV       DR3                                  [@b19-cmed-4-2011-039]
  16         46        M            3                                 ND                    ND                                              (+)                       (+)               PEG-α+ REV       ND                                   [@b19-cmed-4-2011-039]
  17         25        M            4 after IFN                       ND                    ND                                              (−)                       (+)               PEG-α+ REV       DR3, DQ2                             [@b19-cmed-4-2011-039]
  18         44        F            5.5                               ND                    ND                                              (−)                       (+)               PEG-α+ REV       DR3/4, DQ2                           [@b19-cmed-4-2011-039]
  19         46        M            4.5                               ND                    ND                                              (+)                       (+)               PEG-α+REV        ND                                   [@b19-cmed-4-2011-039]
  20         51        M            6                                 (−)                   Nimp                                            (−)                       (+)               PEG-α2b+ REV     ND                                   [@b20-cmed-4-2011-039]
  21         48        M            10                                (−)                   ND                                              (−)                       (+)               PEG-α2b+ REV     DRB1\*0405/\*0901, DQB1\*0401/0303   [@b21-cmed-4-2011-039]
  22         65        M            12                                (−)                   ND                                              (−)                       (+)               PEG-α2b+ REV     DRB1\*0410/\*1407, DQB1\*0402/0503   [@b21-cmed-4-2011-039]
  23         53        F            3                                 (−)                   Nimp                                            ND                        (+)               PEG-α+ REV       DRB1\*0405/0901, DQB1\*0401/0303     [@b22-cmed-4-2011-039]
  24         46        F            13                                (−)                   Imp                                             ND                        (+)               PEG-α2a+ REV     DRB1\*0405/0406, DQB1\*0302/0401     [@b23-cmed-4-2011-039]
  25         67        F            4                                 (−)                   Nimp                                            ND                        (+)               PEG-α2a+ REV     DRB1\*0901/1302, DQB1\*0303/0604     [@b23-cmed-4-2011-039]
  26         46        F            7                                 (−)                   Nimp                                            ND                        (+)               PEG-α2b+ REV     DrB1\*0407/0405, DQB1\*0301/0303     [@b24-cmed-4-2011-039]
  27         55        F            6                                 (+)                   Nimp                                            ND                        (+)               PEG-α2a+ REV     DrB1\*0405/1302, DQB1\*0401/0604     [@b25-cmed-4-2011-039]
  Our case   63        M            4                                 (+)                   Nimp                                            ND                        (+)               PEG-α+ REV       DrB1\*0101/\*0405                    

**Abbreviations:** T1DM, type1 diabetes mellitus; IFN, interferon; M, male; F, female; ND, not determined; Nimp, no improvement; Imp, improvement; PEG, peg-interferon; REV, ribavirin.
